Do analysts rate QNCX or OSRH?

Quince Therapeutics presently has a consensus price target of $206.71, indicating a potential upside of 673.63%. Given Quince Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Quince Therapeutics is more favorable than OSR. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quince Therapeutics 2 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 2.62 OSR 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer SGMO or OSRH?

Sangamo Therapeutics currently has a consensus price target of $5.50, suggesting a potential upside of 7,332.43%. Given Sangamo Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Sangamo Therapeutics is more favorable than OSR. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sangamo Therapeutics 2 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.75 OSR 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is SGMO or OSRH more profitable?

Sangamo Therapeutics has a net margin of -310.81% compared to OSR's net margin of -593.15%. OSR's return on equity of -8.36% beat Sangamo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Sangamo Therapeutics -310.81% -2,662.06% -132.12% OSR -593.15% -8.36% -6.24%

Do analysts rate OSRH or BRNS?

Barinthus Biotherapeutics has a consensus target price of $4.00, suggesting a potential upside of 440.47%. Given Barinthus Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Barinthus Biotherapeutics is more favorable than OSR. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OSR 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Barinthus Biotherapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts recommend EVAX or OSRH?

Evaxion A/S currently has a consensus price target of $11.00, indicating a potential upside of 248.10%. Given Evaxion A/S's stronger consensus rating and higher probable upside, analysts clearly believe Evaxion A/S is more favorable than OSR. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evaxion A/S 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 OSR 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, EVAX or OSRH?

Evaxion A/S has higher revenue and earnings than OSR. Evaxion A/S is trading at a lower price-to-earnings ratio than OSR, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evaxion A/S $7.53M 3.79 -$7.71M -$1.21 N/A OSR $1.81M 4.17 -$27.06M -$0.37 N/A

Is EVAX or OSRH more profitable?

Evaxion A/S has a net margin of 0.00% compared to OSR's net margin of -593.15%. OSR's return on equity of -8.36% beat Evaxion A/S's return on equity. Company Net Margins Return on Equity Return on Assets Evaxion A/S N/A -61.43% -34.23% OSR -593.15% -8.36% -6.24%

Do analysts rate OSRH or ATYR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OSR 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 aTyr Pharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67

Which has preferable earnings and valuation, OSRH or ATYR?

OSR has higher revenue and earnings than aTyr Pharma. OSR is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OSR $1.81M 4.17 -$27.06M -$0.37 N/A aTyr Pharma $190K 143.68 -$74.12M -$0.62 N/A

Is OSRH or ATYR more profitable?

aTyr Pharma has a net margin of 0.00% compared to OSR's net margin of -593.15%. OSR's return on equity of -8.36% beat aTyr Pharma's return on equity. Company Net Margins Return on Equity Return on Assets OSR -593.15% -8.36% -6.24% aTyr Pharma N/A -95.89% -69.67%

OSR (OSRH) Competitors

$0.21 0.00 (-1.16%)

As of 10:51 AM Eastern

Compare

OSRH vs. QNCX, SGMO, BRNS, EVAX, and ATYR

Should you buy OSR stock or one of its competitors? OSR's main competitors and comparable companies include Quince Therapeutics (QNCX), Sangamo Therapeutics (SGMO), Barinthus Biotherapeutics (BRNS), Evaxion A/S (EVAX), and aTyr Pharma (ATYR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does OSR compare to Quince Therapeutics?

Quince Therapeutics (NASDAQ:QNCX) and OSR (NASDAQ:OSRH) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability.

Quince Therapeutics has a beta of 1.33, meaning that its share price is 33% more volatile than the broader market. Comparatively, OSR has a beta of 0.48, meaning that its share price is 52% less volatile than the broader market.

OSR has higher revenue and earnings than Quince Therapeutics. OSR is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quince Therapeutics	N/A	N/A	-$83.98M	-$156.71	N/A
OSR	$1.81M	4.17	-$27.06M	-$0.37	N/A

Quince Therapeutics presently has a consensus price target of $206.71, indicating a potential upside of 673.63%. Given Quince Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Quince Therapeutics is more favorable than OSR.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quince Therapeutics	2 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.62
OSR	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

30.8% of Quince Therapeutics shares are held by institutional investors. Comparatively, 55.3% of OSR shares are held by institutional investors. 5.6% of Quince Therapeutics shares are held by company insiders. Comparatively, 36.9% of OSR shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Quince Therapeutics has a net margin of 0.00% compared to OSR's net margin of -593.15%. Quince Therapeutics' return on equity of 0.00% beat OSR's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quince Therapeutics	N/A	N/A	-133.84%
OSR	-593.15%	-8.36%	-6.24%

In the previous week, Quince Therapeutics had 5 more articles in the media than OSR. MarketBeat recorded 5 mentions for Quince Therapeutics and 0 mentions for OSR. Quince Therapeutics' average media sentiment score of 0.76 beat OSR's score of 0.00 indicating that Quince Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Quince Therapeutics	Positive
OSR	Neutral

Summary

Quince Therapeutics beats OSR on 10 of the 16 factors compared between the two stocks.

How does OSR compare to Sangamo Therapeutics?

Sangamo Therapeutics (NASDAQ:SGMO) and OSR (NASDAQ:OSRH) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, dividends, institutional ownership and analyst recommendations.

Sangamo Therapeutics currently has a consensus price target of $5.50, suggesting a potential upside of 7,332.43%. Given Sangamo Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Sangamo Therapeutics is more favorable than OSR.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sangamo Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
OSR	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Sangamo Therapeutics has a net margin of -310.81% compared to OSR's net margin of -593.15%. OSR's return on equity of -8.36% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%
OSR	-593.15%	-8.36%	-6.24%

Sangamo Therapeutics has a beta of 1.3, suggesting that its stock price is 30% more volatile than the broader market. Comparatively, OSR has a beta of 0.48, suggesting that its stock price is 52% less volatile than the broader market.

In the previous week, Sangamo Therapeutics' average media sentiment score of 0.00 equaled OSR'saverage media sentiment score.

Company	Overall Sentiment
Sangamo Therapeutics	Neutral
OSR	Neutral

56.9% of Sangamo Therapeutics shares are owned by institutional investors. Comparatively, 55.3% of OSR shares are owned by institutional investors. 4.1% of Sangamo Therapeutics shares are owned by insiders. Comparatively, 36.9% of OSR shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

OSR has lower revenue, but higher earnings than Sangamo Therapeutics. OSR is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sangamo Therapeutics	$39.55M	0.78	-$122.93M	-$0.38	N/A
OSR	$1.81M	4.17	-$27.06M	-$0.37	N/A

Summary

Sangamo Therapeutics beats OSR on 8 of the 14 factors compared between the two stocks.

How does OSR compare to Barinthus Biotherapeutics?

OSR (NASDAQ:OSRH) and Barinthus Biotherapeutics (NASDAQ:BRNS) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment.

55.3% of OSR shares are owned by institutional investors. Comparatively, 25.2% of Barinthus Biotherapeutics shares are owned by institutional investors. 36.9% of OSR shares are owned by company insiders. Comparatively, 8.5% of Barinthus Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, OSR's average media sentiment score of 0.00 equaled Barinthus Biotherapeutics'average media sentiment score.

Company	Overall Sentiment
OSR	Neutral
Barinthus Biotherapeutics	Neutral

OSR has a beta of 0.48, suggesting that its stock price is 52% less volatile than the broader market. Comparatively, Barinthus Biotherapeutics has a beta of -0.37, suggesting that its stock price is 137% less volatile than the broader market.

Barinthus Biotherapeutics has a consensus target price of $4.00, suggesting a potential upside of 440.47%. Given Barinthus Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Barinthus Biotherapeutics is more favorable than OSR.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OSR	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Barinthus Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

OSR has higher revenue and earnings than Barinthus Biotherapeutics. Barinthus Biotherapeutics is trading at a lower price-to-earnings ratio than OSR, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OSR	$1.81M	4.17	-$27.06M	-$0.37	N/A
Barinthus Biotherapeutics	N/A	N/A	-$66.43M	-$1.03	N/A

Barinthus Biotherapeutics has a net margin of 0.00% compared to OSR's net margin of -593.15%. OSR's return on equity of -8.36% beat Barinthus Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OSR	-593.15%	-8.36%	-6.24%
Barinthus Biotherapeutics	N/A	-59.15%	-43.80%

Summary

OSR beats Barinthus Biotherapeutics on 9 of the 13 factors compared between the two stocks.

How does OSR compare to Evaxion A/S?

Evaxion A/S (NASDAQ:EVAX) and OSR (NASDAQ:OSRH) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings and valuation.

In the previous week, Evaxion A/S had 2 more articles in the media than OSR. MarketBeat recorded 2 mentions for Evaxion A/S and 0 mentions for OSR. Evaxion A/S's average media sentiment score of 0.00 equaled OSR'saverage media sentiment score.

Company	Overall Sentiment
Evaxion A/S	Neutral
OSR	Neutral

Evaxion A/S currently has a consensus price target of $11.00, indicating a potential upside of 248.10%. Given Evaxion A/S's stronger consensus rating and higher probable upside, analysts clearly believe Evaxion A/S is more favorable than OSR.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evaxion A/S	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
OSR	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

11.0% of Evaxion A/S shares are owned by institutional investors. Comparatively, 55.3% of OSR shares are owned by institutional investors. 41.6% of Evaxion A/S shares are owned by company insiders. Comparatively, 36.9% of OSR shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Evaxion A/S has higher revenue and earnings than OSR. Evaxion A/S is trading at a lower price-to-earnings ratio than OSR, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evaxion A/S	$7.53M	3.79	-$7.71M	-$1.21	N/A
OSR	$1.81M	4.17	-$27.06M	-$0.37	N/A

Evaxion A/S has a net margin of 0.00% compared to OSR's net margin of -593.15%. OSR's return on equity of -8.36% beat Evaxion A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evaxion A/S	N/A	-61.43%	-34.23%
OSR	-593.15%	-8.36%	-6.24%

Evaxion A/S has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market. Comparatively, OSR has a beta of 0.48, suggesting that its stock price is 52% less volatile than the broader market.

Summary

Evaxion A/S beats OSR on 9 of the 15 factors compared between the two stocks.

How does OSR compare to aTyr Pharma?

OSR (NASDAQ:OSRH) and aTyr Pharma (NASDAQ:ATYR) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, media sentiment, risk and valuation.

55.3% of OSR shares are owned by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are owned by institutional investors. 36.9% of OSR shares are owned by insiders. Comparatively, 5.0% of aTyr Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

OSR has higher revenue and earnings than aTyr Pharma. OSR is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OSR	$1.81M	4.17	-$27.06M	-$0.37	N/A
aTyr Pharma	$190K	143.68	-$74.12M	-$0.62	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OSR	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
aTyr Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

aTyr Pharma has a net margin of 0.00% compared to OSR's net margin of -593.15%. OSR's return on equity of -8.36% beat aTyr Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OSR	-593.15%	-8.36%	-6.24%
aTyr Pharma	N/A	-95.89%	-69.67%

In the previous week, aTyr Pharma had 1 more articles in the media than OSR. MarketBeat recorded 1 mentions for aTyr Pharma and 0 mentions for OSR. aTyr Pharma's average media sentiment score of 0.59 beat OSR's score of 0.00 indicating that aTyr Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
OSR	Neutral
aTyr Pharma	Positive

OSR has a beta of 0.48, meaning that its share price is 52% less volatile than the broader market. Comparatively, aTyr Pharma has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market.

Summary

aTyr Pharma beats OSR on 10 of the 16 factors compared between the two stocks.

Get OSR News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OSRH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OSRH vs. The Competition

Export

Metric	OSR	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$7.38M	$3.81B	$7.12B	$13.32B
Dividend Yield	N/A	3.66%	2.53%	16.47%
P/E Ratio	-0.57	13.71	275.34	26.03
Price / Sales	4.08	1,189.72	575.56	85.81
Price / Cash	N/A	118.37	77.41	52.81
Price / Book	0.06	16.06	10.76	6.24
Net Income	-$27.06M	-$22.65M	$3.50B	$381.89M
7 Day Performance	-14.98%	-3.67%	-1.99%	-1.29%
1 Month Performance	3.96%	-12.91%	-7.52%	-5.52%
1 Year Performance	-67.29%	8.61%	2.87%	-1.47%

OSR Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OSRH OSR	0.0834 of 5 stars	$0.21 -1.2%	N/A	-64.5%	$7.46M	$1.81M	N/A	N/A	Gap Down
QNCX Quince Therapeutics	3.6594 of 5 stars	$31.00 +3.3%	$206.71 +566.8%	-92.5%	$31.53M	N/A	N/A	38	News Coverage
SGMO Sangamo Therapeutics	1.0168 of 5 stars	$0.07 flat	$5.50 +7,332.4%	N/A	$30.66M	$39.55M	N/A	480
BRNS Barinthus Biotherapeutics	1.7526 of 5 stars	$0.74 flat	$4.00 +440.5%	N/A	$30.23M	N/A	N/A	107
EVAX Evaxion A/S	2.0162 of 5 stars	$3.34 +2.5%	$11.00 +229.3%	-44.8%	$30.13M	$7.53M	N/A	46	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OSRH) was last updated on 10/8/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

OSR (OSRH) Competitors

OSRH vs. QNCX, SGMO, BRNS, EVAX, and ATYR

How does OSR compare to Quince Therapeutics?

Summary

How does OSR compare to Sangamo Therapeutics?

Summary

How does OSR compare to Barinthus Biotherapeutics?

Summary

How does OSR compare to Evaxion A/S?

Summary

How does OSR compare to aTyr Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OSRH vs. The Competition

OSR Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

OSR (OSRH) Competitors

OSRH vs. QNCX, SGMO, BRNS, EVAX, and ATYR

How does OSR compare to Quince Therapeutics?

Which has more risk and volatility, QNCX or OSRH?

Which has stronger earnings & valuation, QNCX or OSRH?

Do analysts rate QNCX or OSRH?

Do insiders and institutionals have more ownership in QNCX or OSRH?

Is QNCX or OSRH more profitable?

Does the media prefer QNCX or OSRH?

Summary

How does OSR compare to Sangamo Therapeutics?

Do analysts prefer SGMO or OSRH?

Is SGMO or OSRH more profitable?

Which has more risk & volatility, SGMO or OSRH?

Does the media prefer SGMO or OSRH?

Do institutionals & insiders hold more shares of SGMO or OSRH?

Which has better earnings and valuation, SGMO or OSRH?

Summary

How does OSR compare to Barinthus Biotherapeutics?

Do insiders & institutionals hold more shares of OSRH or BRNS?

Does the media favor OSRH or BRNS?

Which has more risk & volatility, OSRH or BRNS?

Do analysts rate OSRH or BRNS?

Which has stronger valuation & earnings, OSRH or BRNS?

Is OSRH or BRNS more profitable?

Summary

How does OSR compare to Evaxion A/S?

Does the media refer more to EVAX or OSRH?

Do analysts recommend EVAX or OSRH?

Do insiders and institutionals have more ownership in EVAX or OSRH?

Which has preferable valuation and earnings, EVAX or OSRH?

Is EVAX or OSRH more profitable?

Which has more risk & volatility, EVAX or OSRH?

Summary

How does OSR compare to aTyr Pharma?

Do insiders & institutionals have more ownership in OSRH or ATYR?

Which has preferable earnings and valuation, OSRH or ATYR?

Do analysts rate OSRH or ATYR?

Is OSRH or ATYR more profitable?

Does the media favor OSRH or ATYR?

Which has more risk & volatility, OSRH or ATYR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OSRH vs. The Competition

OSR Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools